Co-Diagnostics, Inc. to Participate in D. Boral Inaugural Global Conference
Co-Diagnostics (NASDAQ: CODX) announced its participation in the D. Boral Capital Inaugural Global Conference on May 14, 2025, in New York City. The conference aims to connect emerging growth companies with institutional investors. Company representatives will engage in one-on-one meetings to showcase their value proposition and introduce their upcoming Co-Dx PCR testing platform.
The company notes that their PCR platform, which includes the PCR Home™, PCR Pro™, mobile app, and associated tests, is currently pending regulatory review by the FDA and other bodies and is not yet commercially available.
Co-Diagnostics (NASDAQ: CODX) ha annunciato la sua partecipazione al D. Boral Capital Inaugural Global Conference il 14 maggio 2025 a New York City. La conferenza ha l'obiettivo di mettere in contatto aziende in crescita con investitori istituzionali. I rappresentanti dell'azienda parteciperanno a incontri individuali per presentare la loro proposta di valore e introdurre la futura piattaforma di test Co-Dx PCR.
L'azienda segnala che la loro piattaforma PCR, che include PCR Home™, PCR Pro™, l'app mobile e i test correlati, è attualmente in fase di revisione regolatoria da parte della FDA e di altri enti e non è ancora disponibile sul mercato.
Co-Diagnostics (NASDAQ: CODX) anunció su participación en la Conferencia Global Inaugural D. Boral Capital el 14 de mayo de 2025 en la ciudad de Nueva York. La conferencia tiene como objetivo conectar empresas emergentes con inversores institucionales. Los representantes de la empresa participarán en reuniones individuales para presentar su propuesta de valor e introducir su próxima plataforma de pruebas Co-Dx PCR.
La compañía señala que su plataforma PCR, que incluye PCR Home™, PCR Pro™, la aplicación móvil y las pruebas asociadas, está actualmente pendiente de revisión regulatoria por parte de la FDA y otros organismos, y aún no está disponible comercialmente.
Co-Diagnostics (NASDAQ: CODX)는 2025년 5월 14일 뉴욕시에서 열리는 D. Boral Capital Inaugural Global Conference에 참여한다고 발표했습니다. 이 컨퍼런스는 신생 성장 기업과 기관 투자자들을 연결하는 것을 목표로 합니다. 회사 대표들은 일대일 미팅을 통해 자사의 가치 제안을 소개하고 다가오는 Co-Dx PCR 테스트 플랫폼을 선보일 예정입니다.
회사는 PCR 플랫폼(PCR Home™, PCR Pro™, 모바일 앱 및 관련 테스트 포함)이 현재 FDA 및 기타 기관의 규제 검토를 받고 있으며 아직 상업적으로 출시되지 않았다고 밝혔습니다.
Co-Diagnostics (NASDAQ : CODX) a annoncé sa participation à la D. Boral Capital Inaugural Global Conference le 14 mai 2025 à New York. Cette conférence vise à connecter les entreprises en croissance avec des investisseurs institutionnels. Les représentants de la société tiendront des réunions individuelles pour présenter leur proposition de valeur et introduire leur prochaine plateforme de tests Co-Dx PCR.
La société précise que leur plateforme PCR, comprenant PCR Home™, PCR Pro™, l'application mobile et les tests associés, est actuellement en cours d'examen réglementaire par la FDA et d'autres organismes, et n'est pas encore disponible commercialement.
Co-Diagnostics (NASDAQ: CODX) kündigte seine Teilnahme an der D. Boral Capital Inaugural Global Conference am 14. Mai 2025 in New York City an. Die Konferenz hat zum Ziel, aufstrebende Wachstumsunternehmen mit institutionellen Investoren zu vernetzen. Unternehmensvertreter werden Einzelgespräche führen, um ihren Wertvorschlag zu präsentieren und ihre kommende Co-Dx PCR-Testplattform vorzustellen.
Das Unternehmen weist darauf hin, dass ihre PCR-Plattform, zu der PCR Home™, PCR Pro™, die mobile App und zugehörige Tests gehören, derzeit einer behördlichen Prüfung durch die FDA und andere Stellen unterliegt und noch nicht kommerziell verfügbar ist.
- None.
- None.
Salt Lake City, Utah, May 14, 2025 (GLOBE NEWSWIRE) -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the “Company” or “Co-Dx”), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that they will be participating in the D. Boral Capital (“DBC”) Inaugural Global Conference on May 14, 2025 in New York City.
The DBC conference connects emerging growth issuers across multiple sectors with institutional investors. Company representatives will be participating in one-on-one meetings to introduce institutions to the Company’s value proposition and to the upcoming Co-Dx PCR* testing platform.
More information about the conference can be found here.
*The Co-Dx PCR platform (including the PCR Home™, PCR Pro™, mobile app, and all associated tests) is subject to review by the FDA and/or other regulatory bodies and is not yet available for sale.
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets state-of-the-art diagnostics technologies. The Company’s technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform and to identify genetic markers for use in applications other than infectious disease.
Please note that we disclaim any responsibility for the content of external links provided in this press release. These links are provided solely for the reader’s convenience and do not constitute an endorsement by the Company.
Company Contact:
Andrew Benson
Head of Investor Relations
+1.801.438.1036
FAQ
What is the purpose of Co-Diagnostics (CODX) participating in the D. Boral Conference?
When and where is the D. Boral Capital Inaugural Global Conference featuring CODX taking place?
What products will Co-Diagnostics (CODX) showcase at the D. Boral conference?
Is the Co-Dx PCR testing platform currently available for purchase?
